- Home
- NNBR vs PLX Comparison
NNBR vs PLX Comparison
Compare NNBR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- PLX
- Stock Information
- Founded
- NNBR 1980
- PLX 1993
- Country
- NNBR United States
- PLX Israel
- Employees
- NNBR N/A
- PLX N/A
- Industry
- NNBR Industrial Machinery/Components
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNBR Industrials
- PLX Health Care
- Exchange
- NNBR Nasdaq
- PLX Nasdaq
- Market Cap
- NNBR 149.8M
- PLX 160.2M
- IPO Year
- NNBR 1994
- PLX 1998
- Fundamental
- Price
- NNBR $2.26
- PLX $2.57
- Analyst Decision
- NNBR
- PLX Strong Buy
- Analyst Count
- NNBR 0
- PLX 1
- Target Price
- NNBR N/A
- PLX $15.00
- AVG Volume (30 Days)
- NNBR 156.2K
- PLX 791.9K
- Earning Date
- NNBR 03-05-2025
- PLX 03-17-2025
- Dividend Yield
- NNBR N/A
- PLX N/A
- EPS Growth
- NNBR N/A
- PLX N/A
- EPS
- NNBR N/A
- PLX 0.04
- Revenue
- NNBR $464,290,000.00
- PLX $53,399,000.00
- Revenue This Year
- NNBR $3.17
- PLX $67.17
- Revenue Next Year
- NNBR $5.90
- PLX $55.31
- P/E Ratio
- NNBR N/A
- PLX $69.84
- Revenue Growth
- NNBR N/A
- PLX N/A
- 52 Week Low
- NNBR $2.25
- PLX $0.82
- 52 Week High
- NNBR $4.86
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- NNBR 31.26
- PLX 58.33
- Support Level
- NNBR $2.38
- PLX $2.24
- Resistance Level
- NNBR $2.67
- PLX $2.62
- Average True Range (ATR)
- NNBR 0.14
- PLX 0.15
- MACD
- NNBR -0.01
- PLX 0.03
- Stochastic Oscillator
- NNBR 2.27
- PLX 82.08
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets. It also operates in China, Mexico, Brazil, Germany, and other countries.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.